

Anti-Human PDGFD Polyclonal Antibody**Polyclonal Antibody****Cat.NO.: PA06438**

3th Edition

Description:The protein encoded by this gene is a member of the platelet-derived growth factor family. The four members of this family are mitogenic factors for cells of mesenchymal origin and are characterized by a core motif of eight cysteines, seven of which are found in this factor. This gene product only forms homodimers and, therefore, does not dimerize with the other three family members. It differs from alpha and beta members of this family in having an unusual N-terminal domain, the CUB domain. Two splice variants have been identified for this gene. PDGFD (Platelet Derived Growth Factor D) is a Protein Coding gene. Diseases associated with PDGFD include Mesangial Proliferative Glomerulonephritis and Prostate Cancer. Among its related pathways are Signaling in Gap Junctions and GPCR Pathway. GO annotations related to this gene include growth factor activity and platelet-derived growth factor receptor binding. An important paralog of this gene is PDGFC.

Antigen:Synthesized peptide derived from the C-terminal region of human PDGF-D.

Form:

How to use:1.0 ml distilled water will be added to the product

Stability: Lyophilized product, 5 years at 2 – 8°C; Solution, 2 years at –20°C

Dilution:PBS (pH7.4) containing 1% BSA

Application:This antibody can be used for western blotting in concentration of 1?5?g/ml.

Specificity:Expressed at high levels in the heart, pancreas, adrenal gland and ovary and at low levels in placenta, liver, kidney, prostate, testis, small intestine, spleen and colon. In the kidney, expressed by the visceral epithelial cells of the glomeruli. A widespread expression is also seen in the medial smooth muscle cells of arteries and arterioles, as well as in smooth muscle cells of vasa rectae in the medullary area. Expressed in the adventitial connective tissue surrounding the suprarenal artery. In chronic obstructive nephropathy, a persistent expression is seen in glomerular visceral epithelial cells and vascular smooth muscle cells, as well as de novo expression by periglomerular interstitial cells and by some neointimal cells of arteriosclerotic vessels. Expression in normal prostate is seen preferentially in the mesenchyme of the gland while expression is increased and more profuse in prostate carcinoma. Expressed in many ovarian, lung, renal and brain cancer-derived cell lines.